Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.990
+0.010 (0.20%)
Feb 27, 2026, 4:00 PM EST - Market closed
Radiopharm Theranostics Revenue
Radiopharm Theranostics had revenue of 10.07M AUD in the half year ending June 30, 2025, with 417.19% growth. This brings the company's revenue in the last twelve months to 15.66M, up 2,668.27% year-over-year. In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M with 538.86% growth.
Revenue (ttm)
15.66M AUD
Revenue Growth
+2,668.27%
P/S Ratio
5.56
Revenue / Employee
1,118,615 AUD
Employees
14
Market Cap
58.07M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 30.91M |
| ImmuCell | 27.77M |
| TScan Therapeutics | 8.42M |
| Alterity Therapeutics | 4.96M |
| Lipocine | 4.32M |
| Nutriband | 2.28M |
| BeyondSpring | 1.88M |
| Spruce Biosciences | 697.00K |
RADX News
- 4 weeks ago - Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates - GlobeNewsWire
- 6 weeks ago - RAD Increases Ownership in Radiopharm Ventures to 87.5% - GlobeNewsWire
- 2 months ago - Why Is Radiopharm Theranostics Stock Rallying Over 140%? - Benzinga
- 2 months ago - Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases - GlobeNewsWire
- 3 months ago - Radiopharm Theranostics (RADX): Analyst Maintains 'Buy' as Price Target Adjusts | RADX Stock News - GuruFocus
- 4 months ago - Lantheus (LNTH) Commits to Significant Investment in Radiopharm Theranostics - GuruFocus
- 4 months ago - Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan - GlobeNewsWire
- 4 months ago - Regal-backed biotech Radiopharm Theranostics launches $35m placement - The Australian Financial Review